Cancer Family
Hepatobiliary Neoplasm
CI-CAN-00000198Explore in graph →
Non-malignant1,188 active trials17 approved drugs42 evidence items
- NCIt
- C8614
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000198Explore in graph →
Clinical trials
5,266 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05536427 | Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 24 | Peking Union Medical College HospitalOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT05416073 | Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma(TACE-HAIC) | unknown | Phase 4 | 70 | The Second Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 |
| Feb 24, 2023 |
| clinicaltrials |
| NCT05738447 | Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular Carcinoma | unknown | Phase 1 | 9 | West China HospitalOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT05738772 | Diagnostic Accuracy of APAC, ASAP and GALAD Scores in Hepatocellular Carcinoma Among Cirrhotic Patients | unknown | — | 90 | Sohag UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT05519319 | Safety and Efficacy of PDT vs RFA vs PDT+RFA for the Treatment of Extrahepatic Cholangiocarcinoma | unknown | N/A | 70 | First People's Hospital of HangzhouOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04387695 | SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT | unknown | Phase 3 | 54 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04992143 | TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC | unknown | Phase 2 | 20 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05729867 | Efficacy and Safety of a Fully Covered Self-Expandable Metal Stent for Unresectable HCC | unknown | N/A | 50 | Seoul National University HospitalOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05709886 | A Prospective, Single-arm, Multicenter Clinical Trial of Safety and Effectiveness of EUS-LA for Liver Cancer | unknown | N/A | 69 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT03766555 | Microwave Ablation Versus Liver Resection For Early Hepatocellular Carcinoma in Patients With Borderline Liver Function | unknown | N/A | 76 | Chinese University of Hong KongOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05543304 | Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC) | unknown | — | 200 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05721300 | Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer | unknown | N/A | 2,215 | Zhongshan Hospital (Xiamen), Fudan UniversityOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT05721963 | Study on the Accuracy of Proteomics in Evaluating Lymph Node Metastasis Status in Cholangiocarcinoma Patients | unknown | — | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT04417764 | TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma. | unknown | Phase 1 | 10 | Central South UniversityOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT05719480 | A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Liver Cancer | unknown | — | 2,000 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT05029973 | HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05225116 | Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT | unknown | Phase 1 | 20 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05716620 | Utility of Abbreviated Magnetic Resonance Imaging as a Screening Tool for Hepatocellular Carcinoma in Cirrhotic Patients | unknown | — | 380 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05718115 | Deep Learning Radiogenomics For Individualized Therapy in Unresectable Gallbladder Cancer | unknown | — | 75 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05718349 | FGF19 in Obstructive Cholestasis: "Unveil the Signal"(FOCUS) | unknown | — | 81 | Nicole HildebrandOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT03099564 | Pembrolizumab Plus Y90 Radioembolization in HCC Subjects | unknown | Early Phase 1 | 30 | Ashwin SomasundaramOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT04911959 | Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC | unknown | Phase 1 / Phase 2 | 50 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT04612504 | SynOV1.1 Intratumoral Injection Study | unknown | Phase 1 | 15 | Beijing Syngentech Co., Ltd.INDUSTRY | 1 | Feb 2, 2023 | clinicaltrials |
| NCT05701553 | Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma | unknown | — | 20 | Shanghai Zhongshan HospitalOTHER | 1 | Feb 2, 2023 | clinicaltrials |
| NCT05609695 | Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma | unknown | — | 100 | Sun Yat-sen UniversityOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT02125396 | Adjuvant Radiotherapy Comparing TACE for Curative HCC(ARTC-HCC) | unknown | Phase 3 | 150 | Guangxi Medical UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT04984980 | Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer | unknown | Phase 2 | 37 | Fudan UniversityOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05131698 | Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma | unknown | Early Phase 1 | 31 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05312216 | Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 25 | Zhejiang UniversityOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05694949 | Main Postoperative Complications After COVID-19 | unknown | — | 100,000 | RenJi HospitalOTHER | 0 | Jan 25, 2023 | clinicaltrials |
| NCT05697237 | Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma | unknown | N/A | 60 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Jan 25, 2023 | clinicaltrials |
| NCT05693519 | GastroIntestinal Cancer in Children and Adolescents(GICCA) | unknown | — | 2,500 | Paul G. Kemps, MDOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT04213118 | Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence(ALTER-H-004) | unknown | Phase 2 | 30 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05237193 | A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up | unknown | — | 400 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05677724 | Single-cell RNA Sequencing Resolves the Regulatory Role of HBV on the Hepatocellular Carcinoma Immune Microenvironment | unknown | — | 20 | Fubing WangOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05672537 | Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk | unknown | Phase 2 | 70 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT05667350 | AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Biliary Tract Cancer (ASCEND-BTC) | unknown | — | 492 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Dec 30, 2022 | clinicaltrials |
| NCT05668793 | GNB4 and Riplet Gene Methylation Combined Detection Kit (Fluorescence PCR Method) | unknown | — | 1,000 | Wuhan Ammunition Life-tech Co., LtdINDUSTRY | 0 | Dec 30, 2022 | clinicaltrials |
| NCT05280444 | Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma | unknown | Phase 2 / Phase 3 | 216 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05344924 | TACE Combined With Penpulimab and Anlotinib for Advanced HCC | unknown | Phase 2 / Phase 3 | 109 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05557656 | A Real World Study of Regogfinib in HCC | unknown | — | 800 | Zhongda HospitalOTHER | 0 | Dec 29, 2022 | clinicaltrials |
| NCT05631613 | Lipiodol-TACE With Idarubicin Based On a Specific Emulsion Ratio for Hepatocellular Carcinoma | unknown | — | 40 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05662488 | FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination Therapy | unknown | — | 25 | Peking Union Medical College HospitalOTHER | 1 | Dec 22, 2022 | clinicaltrials |
| NCT05653817 | Advanced or Metastatic Cholangiocarcinoma | unknown | N/A | 60 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Dec 16, 2022 | clinicaltrials |
| NCT05578430 | AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) | unknown | Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 0 | Dec 15, 2022 | clinicaltrials |
| NCT05361538 | Study of Microwave Spherical Ablation and Traditional Microwave Ablation in Single Hepatocellular Carcinoma ≤5cm | unknown | N/A | 60 | Tianjin Third Central HospitalOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05650151 | Peri-operative Vitamin D Therapy for Hepatectomy | unknown | N/A | 200 | National Taiwan University HospitalOTHER | 0 | Dec 14, 2022 | clinicaltrials |
| NCT04212273 | Diagnostic Efficacies of Sonazoid-CEUS and EOB-MRI in Patients With High Risk of HCC | unknown | N/A | 200 | Tianjin Third Central HospitalOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT05360420 | Diagnosis of Nodules ≤2 cm Based on US and CEUS Compared With Current Clinical Procedure | unknown | N/A | 6,730 | Tianjin Third Central HospitalOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT05643417 | Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy | unknown | Phase 1 | 80 | Fudan UniversityOTHER | 1 | Dec 8, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 2, 2023source: clinicaltrials